Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV003162259 | SCV003854269 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2022-12-29 | criteria provided, single submitter | clinical testing | The c.2057-2A>G intronic variant results from an A to G substitution two nucleotides upstream from coding exon 17 in the BAP1 gene. This alteration has been observed in at least one individual with a personal and/or family history that is consistent with BAP1-related disease (Ambry internal data). This variant was shown to segregate in a family with numerous melanocytic tumors, melanomas, and uveal melanomas that lacked BAP1 expression in immunohistochemistry (Wiesner T et al. Nat Genet, 2011 Aug;43:1018-21). RNA studies have shown this alteration results in the retention of intron 16 (Ambry internal data; Wiesner T et al. Nat Genet, 2011 Aug;43:1018-21). This alteration occurs at the 3' terminus of the BAP1 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 44 amino acids of the protein. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| OMIM | RCV000023235 | SCV000044526 | pathogenic | BAP1-related tumor predisposition syndrome | 2011-08-28 | no assertion criteria provided | literature only |